Therapeutic Digoxin Level for Atrial Fibrillation
For a patient with atrial fibrillation on digoxin 0.125 mg daily, the therapeutic serum digoxin concentration should be 0.5-0.9 ng/mL, with levels measured at least 12-24 hours after the last dose to allow for tissue distribution. 1
Target Range and Timing
The 2013 ACC/AHA Heart Failure Guidelines consistently recommend targeting plasma concentrations of 0.5-0.9 ng/mL for digoxin therapy 1. This lower range is based on retrospective analyses showing that prevention of worsening heart failure at these lower concentrations (0.5-0.9 ng/mL) was as effective as higher concentrations, while avoiding increased mortality risk seen at levels >1.0 ng/mL 1.
Critical timing consideration: Blood sampling must occur at least 12 hours, and preferably 24 hours, after the previous dose due to digoxin's prolonged tissue distribution phase 2. Sampling earlier than 12 hours will yield falsely elevated concentrations that don't reflect true steady-state tissue levels 2.
Context for Atrial Fibrillation Specifically
For atrial fibrillation rate control, the optimal therapeutic range has not been definitively established 2. The 2014 AATS guidelines note that when digoxin is used for heart failure, the desired range is 0.5-0.9 ng/mL, but acknowledge that no strong relationship exists between serum concentration and rate control efficacy in AF 2. The most recent 2023 ACC/AHA/HRS AF guidelines indicate that increased mortality is associated with plasma concentrations exceeding 1.2 ng/mL 3.
Therefore, for AF patients, aim for the same 0.5-0.9 ng/mL range to balance efficacy with safety, recognizing that rate control may not correlate linearly with serum levels 2.
When to Check Levels After Starting Therapy
After initiating digoxin 0.125 mg daily, steady-state concentrations require approximately 5 half-lives, which takes 1-3 weeks depending on renal function 1. For patients with normal kidney function (half-life ~36 hours), steady state is reached in approximately 7-10 days 2.
Your patient's level drawn at 1 week is appropriately timed to assess steady-state concentration, assuming normal renal function 2.
Safety Thresholds
- Toxicity risk increases significantly at levels >2.0 ng/mL 1, 4, 5
- However, toxicity can occur at lower levels if hypokalemia, hypomagnesemia, hypothyroidism, or drug interactions are present 1, 4, 5
- Recent evidence suggests mortality risk increases at levels >1.0-1.2 ng/mL 4, 5, 3
Important Caveats for This Patient
Dose adjustment factors to verify:
- Age >70 years requires lower doses (0.125 mg daily or every other day) 1
- Impaired renal function necessitates dose reduction 1
- Low lean body mass requires lower doses 1
Drug interactions that increase digoxin levels:
- Amiodarone, dronedarone (reduce digoxin dose by 30-50%) 1, 6
- Verapamil, diltiazem, propafenone, flecainide 1, 6
- Clarithromycin, erythromycin, itraconazole 1, 4, 5, 6
Clinical Interpretation Algorithm
If the measured level at 1 week is:
- <0.5 ng/mL: Consider dose increase if inadequate rate control and no contraindications
- 0.5-0.9 ng/mL: Therapeutic range—maintain current dose
- 1.0-1.5 ng/mL: Consider dose reduction to minimize mortality risk, especially if adequate rate control achieved
- >1.5 ng/mL: Reduce dose; assess for toxicity symptoms (nausea, visual changes, arrhythmias)
- >2.0 ng/mL: High risk for toxicity—reduce or hold dose, check electrolytes, assess for symptoms
Remember: Serum concentration should always be interpreted in the overall clinical context, not used in isolation to adjust therapy 7. Rate control efficacy and patient symptoms take precedence over achieving a specific number.